English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Psoriasis and inflammatory bowel diseases share common immunological pathomechanisms and therefore similar treatment options. To assess already existing therapies and their efficacy versus adverse effects and paradoxical reactions in patients presenting with either disease or both. A systematic search of the PubMed and Science.gov databases was performed for the period 2018–2020. Only articles in English were selected. Search terms included a combination of keywords:  adalimumab, infliximab, etanercept, golimumab, certolizumab, ustekinumab, guselkumab, vedolizumab, secukinumab, ixekizumab, brodalumab, acitretin, cyclosporine, methotrexate, apremilast, mycophenolate mofetil, sulfasalazine, hydroxyurea, azathioprine, 6-thioguanine, tacrolimus, leflunomide  and  fumaric acid esters  in combination with each of the following:  paradoxical, psoriasis, psoriatic arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.  Other potentially relevant articles were identified by manually checking the references of the included literature. Recent reviews and meta-analyses, pooled analyses, cohort studies, observational studies, care reports were all included. Psoriasis and IBD can be treated concurrently as they share common inflammatory pathways. TNF-α inhibitors and IL-12/23 have been successful in treating both psoriasis and IBD. IL-17 inhibitors are recognized treatments for psoriasis but have the potential to exacerbate IBD. Newer molecules require further clinical trials and real-life studies in order to confirm their efficacy and safety.

Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review